Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qianlieshutong capsule plus tamsulosin for type III chronic prostatitis
ChiCTR2100041642Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Qianlieshutong and tamsulosin in chronic prostatitis (CP) (2 arms), sponsored by Beijing Hospital. Primary endpoint: NIH Chronic Prostatitis Symptom Index score. Started Jan 2021; status: recruiting.
02
Drugs
Qianlieshutongtamsulosin
03
Conditions
chronic prostatitis (CP)
Beyond the preview
Go deeper on ChiCTR2100041642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041642.